Researchers at Mitsubishi Tanabe Pharma Development America are looking for participants with amyotrophic lateral sclerosis (ALS) to participate in a phase 3 study to evaluate the safety of oral edaravone (Radicava).
Intravenous edaravone is an FDA-approved treatment for ALS shown to slow the decline of physical function. Edaravone is thought to act as a free radical scavenger and prevent oxidative stress damage to neurons.
All participants will receive an oral suspension of edaravone. The study will consist of eight visits total over the course of one year. Throughout the study, participants will continue to see their regular doctor for routine care.
In order to be eligible to participate, candidates must meet the criteria below, along with additional study criteria:
- Must be between ages 18 and 75
- Must be diagnosed with clinically possible, clinically probable, laboratory-supported probable or clinically definite ALS, or familial ALS according to EL Escorial revised criteria
- Must have a disease duration from symptom onset of three years or fewer
- Must be living and functioning independently; the use of supportive tools and adaptive utensils is allowed
- Must have a baseline forced vital capacity percentage (%FVC) greater than or equal to 70%